Unity Biotechnology, Inc.
$0.06+0.00%(+$0.00)
TickerSpark Score
55/100
80
Valuation
50
Profitability
60
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNBX research report →
52-Week Range0% of range
Low $0.05
Current $0.06
High $3.10
Companyunitybiotechnology.com/pipeline
Unity Biotechnology, Inc. is a biotechnology firm developing therapies to slow, halt, or reverse aging-related diseases with programs like senolytic candidates targeting ophthalmologic and neurologic disorders.
- CEO
- Craig R. Jalbert
- IPO
- 2018
- Employees
- 16
- HQ
- San Francisco, CA, US
Price Chart
-96.26% · this period
Valuation
- Market Cap
- $965.60K
- P/E
- -0.21
- P/S
- 2.59
- P/B
- -16.47
- EV/EBITDA
- -1.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 36.60%
- Op Margin
- -1072.36%
- Net Margin
- -1185.39%
- ROE
- -500.62%
- ROIC
- -56.55%
Performance & Tape
- 52W High
- $3.10
- 52W Low
- $0.05
- 50D MA
- $0.07
- 200D MA
- $0.85
- Beta
- 1.19
- Avg Volume
- 81.34K
Get TickerSpark's AI analysis on UNBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our UNBX Coverage
We haven't published any research on UNBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UNBX Report →